{"entity":{"id":"soligenix","kind":"company","name":"Soligenix","aka":["Soligenix, Inc."],"tldr":"Soligenix is a New Jersey company developing HyBryte, a synthetic hypericin ointment activated by visible light, for early-stage cutaneous T-cell lymphoma, tested in the phase 3 FLASH trials.","summary":"Soligenix, based in Princeton and listed on Nasdaq, develops treatments for rare diseases and biodefence. Its lead cancer programme is HyBryte (synthetic hypericin), a photosensitiser applied to skin lesions and activated with visible rather than ultraviolet light, for early-stage mycosis fungoides, the commonest form of cutaneous T-cell lymphoma; the FLASH phase 3 trial met its primary endpoint in 2020 and a confirmatory trial, FLASH2, followed at the FDA's request. It appears on OnCo as a lead sponsor of phase 3 cancer trials on ClinicalTrials.gov.","asOf":"2026-09-11","links":[{"label":"Official website","url":"https://www.soligenix.com"},{"label":"ClinicalTrials.gov: trials led by Soligenix","url":"https://clinicaltrials.gov/search?lead=Soligenix"},{"label":"Wikipedia","url":"https://en.wikipedia.org/wiki/Soligenix"}],"tags":["ctgov-sponsor"],"related":[],"cancers":[],"sections":["radiation","targeted-therapy"],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":["pivotal-trial","clinical-trial"],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":[],"provenance":{"editedBy":"OnCo ingestion (ClinicalTrials.gov v2 + sponsor websites)","editedOn":"2026-09-11"},"hq":"Princeton, NJ","country":"US","companyType":"biotech","website":"https://www.soligenix.com","stage":"public","investors":[],"funding":[]},"route":"/companies/soligenix/","neighbours":{"section":[{"id":"radiation","kind":"section","name":"Radiation Therapy","route":"/fronts/radiation/"},{"id":"targeted-therapy","kind":"section","name":"Targeted Therapy","route":"/fronts/targeted-therapy/"}],"term":[{"id":"clinical-trial","kind":"term","name":"Clinical trial","route":"/terms/clinical-trial/"},{"id":"pivotal-trial","kind":"term","name":"Pivotal (registrational) trial","route":"/terms/pivotal-trial/"}],"trial":[{"id":"nct06470451","kind":"trial","name":"Confirmatory Study of Topical HyBryte™ vs. Placebo for the Treatment of CTCL","route":"/trials/nct06470451/"},{"id":"nct02448381","kind":"trial","name":"FLASH [Fluorescent Light Activated Synthetic Hypericin] Clinical Study: Topical SGX301 (Synthetic Hypericin) for the Treatment of Cutaneous T-Cell Lymphoma (Mycosis Fungoides)","route":"/trials/nct02448381/"},{"id":"nct06149247","kind":"trial","name":"HyBryte (Synthetic Hypericin) Versus Valchlor (Mechlorethamine) in the Treatment of CTCL","route":"/trials/nct06149247/"}],"drug":[{"id":"hypericin-sgx301","kind":"drug","name":"Synthetic hypericin","route":"/drugs/hypericin-sgx301/"}],"cancer":[{"id":"cutaneous-t-cell-lymphoma","kind":"cancer","name":"Cutaneous T-cell lymphoma (mycosis fungoides and Sezary syndrome)","route":"/cancers/cutaneous-t-cell-lymphoma/"}]}}